[go: up one dir, main page]

DE60019577D1 - 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel - Google Patents

4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel

Info

Publication number
DE60019577D1
DE60019577D1 DE60019577T DE60019577T DE60019577D1 DE 60019577 D1 DE60019577 D1 DE 60019577D1 DE 60019577 T DE60019577 T DE 60019577T DE 60019577 T DE60019577 T DE 60019577T DE 60019577 D1 DE60019577 D1 DE 60019577D1
Authority
DE
Germany
Prior art keywords
antitum
agent
tetrahydroindazole derivatives
tetrahydroindazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60019577T
Other languages
English (en)
Other versions
DE60019577T2 (de
Inventor
Paolo Pevarello
Manuela Villa
Mario Varasi
Antonella Isacchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Publication of DE60019577D1 publication Critical patent/DE60019577D1/de
Application granted granted Critical
Publication of DE60019577T2 publication Critical patent/DE60019577T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60019577T 1999-05-12 2000-05-04 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel Expired - Fee Related DE60019577T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9911053.8A GB9911053D0 (en) 1999-05-12 1999-05-12 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
GB9911053 1999-05-12
PCT/EP2000/004208 WO2000069846A1 (en) 1999-05-12 2000-05-04 4,5,6,7-tetrahydroindazole derivatives as antitumor agents

Publications (2)

Publication Number Publication Date
DE60019577D1 true DE60019577D1 (de) 2005-05-25
DE60019577T2 DE60019577T2 (de) 2006-03-09

Family

ID=10853343

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019577T Expired - Fee Related DE60019577T2 (de) 1999-05-12 2000-05-04 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel

Country Status (26)

Country Link
US (1) US6716856B1 (de)
EP (1) EP1177185B1 (de)
JP (1) JP2002544271A (de)
KR (1) KR20010113926A (de)
CN (1) CN1350528A (de)
AR (1) AR023971A1 (de)
AT (1) ATE293618T1 (de)
AU (1) AU4564500A (de)
BR (1) BR0010476A (de)
CA (1) CA2372429A1 (de)
CZ (1) CZ20013970A3 (de)
DE (1) DE60019577T2 (de)
EA (1) EA200101194A1 (de)
ES (1) ES2239595T3 (de)
GB (1) GB9911053D0 (de)
HK (1) HK1045687A1 (de)
HU (1) HUP0201225A3 (de)
IL (1) IL146100A0 (de)
MX (1) MXPA01011441A (de)
NO (1) NO20015477L (de)
NZ (1) NZ514873A (de)
PL (1) PL351611A1 (de)
PT (1) PT1177185E (de)
SK (1) SK15712001A3 (de)
WO (1) WO2000069846A1 (de)
ZA (1) ZA200108530B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236217T3 (es) 2000-04-25 2005-07-16 Bristol-Myers Squibb Company Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
JP2004517840A (ja) * 2000-11-27 2004-06-17 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
DE10148617A1 (de) * 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
AU2004240772B2 (en) 2003-05-22 2011-04-28 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
CN101027301B (zh) * 2004-03-09 2011-06-29 科塞普特治疗公司 稠环氮杂十氢化萘糖皮质激素受体调节剂
ES2527770T3 (es) * 2005-02-25 2015-01-29 Serenex, Inc. Derivados de tetrahidroindolona y tetrahidroindazolona
WO2006133634A1 (en) * 2005-06-14 2006-12-21 Beijing Gylongly Biodemtech Co., Ltd Tetrahydroindole derivatives and tetrahydroindazole derivatives, and use thereof
WO2007009898A1 (en) 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
AU2006292429A1 (en) * 2005-09-16 2007-03-29 Serenex, Inc. Carbazole derivatives
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
US20070207984A1 (en) * 2006-02-27 2007-09-06 Huang Kenneth H Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives
EP1999131B1 (de) 2006-03-03 2013-10-23 Nerviano Medical Sciences S.r.l. Als kinaseinhibitoren wirksame bicyclopyrazole
US20080119457A1 (en) * 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
US20080070930A1 (en) * 2006-08-24 2008-03-20 Huang Kenneth H Pyrimidine and Pyrazine Derivatives
US20080070933A1 (en) * 2006-08-24 2008-03-20 Huang Kenneth H Purine, Pyrimidine, and Azaindole Derivatives
WO2008024970A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
WO2008024980A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
EP2120933B1 (de) 2007-02-27 2015-07-08 Nerviano Medical Sciences S.r.l. Isochinolinopyrrolopyridinone als wirksame kinase-hemmer
EP2003129B1 (de) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-on und 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-on-Derivate
WO2010009985A2 (en) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
WO2010088050A2 (en) 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102311389A (zh) * 2010-06-29 2012-01-11 王小龙 一种氮芳香取代吡唑衍生物、及其合成和抗癌应用
CN103298816A (zh) 2010-12-17 2013-09-11 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物
WO2012094618A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
JP2015520143A (ja) * 2012-05-11 2015-07-16 バイエル ファーマ アクチエンゲゼルシャフト 癌を治療するためのｂｕｂ１阻害薬としての置換されているシクロアルケノピラゾール類
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
MY180141A (en) 2013-11-25 2020-11-23 Corcept Therapeutics Inc Octahydro fused azadecalin glucocorticoid receptor modulators
CA3055076C (en) 2017-03-31 2022-02-22 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
PT3897589T (pt) 2018-12-19 2026-01-21 Corcept Therapeutics Incorporated Formulações farmacêuticas contendo relacorilant, um composto de azadecalina fundido com heteroaril-cetona
CN113490496A (zh) 2019-02-22 2021-10-08 科赛普特治疗学股份有限公司 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途
KR20220113767A (ko) 2019-12-11 2022-08-16 코어셉트 쎄라퓨틱스 인코포레이티드 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법
JP2023507138A (ja) 2019-12-20 2023-02-21 ファイザー・インク ベンゾイミダゾール誘導体
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
IL312348A (en) 2021-10-29 2024-06-01 Arcus Biosciences Inc HIF-2ALPHA inhibitors and methods of using it
JP2025535043A (ja) 2022-10-06 2025-10-22 コーセプト セラピューティクス， インコーポレイテッド グルココルチコイド受容体調節因子の製剤
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657438A (en) * 1968-09-27 1972-04-18 Ciba Geigy Corp Compositions and methods for treating inflammation
US3657270A (en) * 1970-01-16 1972-04-18 Parke Davis & Co 1-phenyl-1h-indazole-4-acetic acids
US3691180A (en) * 1970-07-31 1972-09-12 Ciba Geigy Corp Cycloalkano (c)pyrazoles
JPS60130521A (ja) 1983-12-19 1985-07-12 Morishita Seiyaku Kk 抗癌剤
JPS6299361A (ja) 1985-10-25 1987-05-08 Morishita Seiyaku Kk インデノ〔１，２−ｃ〕ピラゾ−ル誘導体
KR880009024A (ko) 1987-01-27 1988-09-13 게리 디.스트리트 기관지 확장제용 디피라졸
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
EP1023063B1 (de) * 1997-10-06 2003-09-10 Abbott GmbH & Co. KG INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
CZ20013970A3 (cs) 2002-04-17
WO2000069846A1 (en) 2000-11-23
GB9911053D0 (en) 1999-07-14
ATE293618T1 (de) 2005-05-15
US6716856B1 (en) 2004-04-06
NZ514873A (en) 2004-05-28
AR023971A1 (es) 2002-09-04
PT1177185E (pt) 2005-08-31
HUP0201225A2 (en) 2002-08-28
ZA200108530B (en) 2003-02-03
KR20010113926A (ko) 2001-12-28
NO20015477L (no) 2002-01-11
JP2002544271A (ja) 2002-12-24
CA2372429A1 (en) 2000-11-23
HK1045687A1 (zh) 2002-12-06
PL351611A1 (en) 2003-05-05
ES2239595T3 (es) 2005-10-01
NO20015477D0 (no) 2001-11-08
SK15712001A3 (sk) 2002-06-04
IL146100A0 (en) 2002-07-25
MXPA01011441A (es) 2002-10-21
EP1177185A1 (de) 2002-02-06
EP1177185B1 (de) 2005-04-20
DE60019577T2 (de) 2006-03-09
BR0010476A (pt) 2003-07-01
HUP0201225A3 (en) 2003-11-28
CN1350528A (zh) 2002-05-22
AU4564500A (en) 2000-12-05
EA200101194A1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
DE60019577D1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
TR200000520A3 (tr) 4-Fenil-piridin türevleri.
DE60131971D1 (de) 1,3,8-TRIAZA-SPIROi4,5 DECAN-4-ONDERIVATIVE ALS NEUROKININREZEPTORANTAGONISTEN
ATE315036T1 (de) 2,4-diaminopyrimidinderivate als immunosuppressiva
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
DE60009747D1 (de) Admantan-derivate
DE50010060D1 (de) Thiazolylamid-derivate
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
DE50013404D1 (de) Substituierte 2-dialkylaminoalkylbiphenyl-derivate
ATE270270T1 (de) Neuartige phenylalkyloxy-phenyl-derivate
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
EE04089B1 (et) 1,3,4-oksadiasolooni derivaadid
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de) Resorcinderivate
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DK1189886T3 (da) Ethansulfonyl-piperidinderivater
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
DE60000826D1 (de) 14.beta.,17-alpha-hydroxymethylandrostan derivate als androgene
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee